Tor Ketil Larsen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tor Ketil Larsen has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Inge Joa
TIPS, Centre for Clinical Research in Psychosis, Stavanger University Hospital, Stavanger, Norway; Institute of Public Health, Faculty of Health Sciences, University of Stavanger, Stavanger, Norway
2 shared publications - Anne Opsal
Sørlandet Hospital, Addiction Unit, Postbox 416, Kristiansand N-4604, Norway
1 shared publication - Arne Gerdner
Arne Gerdner, Ph.D., professor, School of Health Sciences, Jönköping University , Jönköping , Sweden
1 shared publication - Bakke Elise Aasen Rudshaug
Sørlandet Hospital, Addiction Unit, Postbox 416, Kristiansand N-4604, Norway
1 shared publication - Eirik Kjelby
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
1 shared publication - Else-Marie Løberg
NORMENT Centre of Excellence, Haukeland University Hospital, Bergen, Norway
1 shared publication
Latest Publications
- Open Access
- 1 May 2023
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (3) , 246-258
Antidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders
Background: Depressive symptoms are frequent in schizophrenia and associated with a poorer outcome. Currently, the optimal treatment for depressive symptoms in schizophrenia remains undetermined. Amisulpride, aripiprazole, and olanzapine all have antidepressive pharmacodynamic properties, ranging from serotonergic affinities to limbic dopaminergic selectivity. Consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the Calgary Depression Scale for Schizophrenia sum score in patients within the schizophrenia spectrum. Methods: Psychotic patients within the schizophrenia spectrum were included, and effectiveness was analyzed with latent growth curve modeling. Results: Of the 144 patients, 51 (35%) were women, the mean age was 31.7 (SD 12.7), and 39% were antipsychotic naive. At inclusion, 68 (47%) participants had a Calgary Depression Scale for Schizophrenia sum score >6, indicating severe depressive symptoms. Across the 12-month follow-up, there was a depressive symptom reduction in all medication groups, but no statistically significant differences between the study drugs. Separate analyses of the subcohort with elevated depressive symptoms at inclusion also failed to find differences in depressive symptom reduction between study drugs. The reduction in depressive symptoms mainly occurred within 6 weeks after randomization. Conclusions: There was a reduction in depressive symptoms under treatment with amisulpride, aripiprazole, and olanzapine in acutely psychotic patients with schizophrenia spectrum disorder, but no differences between the drugs.
- 1 May 2023
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 43 (3) , 246-258
Open AccessAntidepressive Effectiveness of Amisulpride, Aripiprazole, and Olanzapine in Patients With Schizophrenia Spectrum Disorders
Background: Depressive symptoms are frequent in schizophrenia and associated with a poorer outcome. Currently, the optimal treatment for depressive symptoms in schizophrenia remains undetermined. Amisulpride, aripiprazole, and olanzapine all have antidepressive pharmacodynamic properties, ranging from serotonergic affinities to limbic dopaminergic selectivity. Consequently, in a 12-month pragmatic, randomized clinical trial, we aimed to investigate differences in antidepressive effectiveness among amisulpride, aripiprazole, and olanzapine as a secondary outcome, measured by change in the Calgary Depression Scale for Schizophrenia sum score in patients within the schizophrenia spectrum. Methods: Psychotic patients within the schizophrenia spectrum were included, and effectiveness was analyzed with latent growth curve modeling. Results: Of the 144 patients, 51 (35%) were women, the mean age was 31.7 (SD 12.7), and 39% were antipsychotic naive. At inclusion, 68 (47%) participants had a Calgary Depression Scale for Schizophrenia sum score >6, indicating severe depressive symptoms. Across the 12-month follow-up, there was a depressive symptom reduction in all medication groups, but no statistically significant differences between the study drugs. Separate analyses of the subcohort with elevated depressive symptoms at inclusion also failed to find differences in depressive symptom reduction between study drugs. The reduction in depressive symptoms mainly occurred within 6 weeks after randomization. Conclusions: There was a reduction in depressive symptoms under treatment with amisulpride, aripiprazole, and olanzapine in acutely psychotic patients with schizophrenia spectrum disorder, but no differences between the drugs.
- Open Access
- 2 May 2017
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 137 (9) , 596
Re: Psykiatriens indre konflikter eksponert
Brev til redaktøren - Helse- og omsorgsdepartementet har pålagt alle helseforetak å innføre medikamentfri behandling av psykoser på tross av sterke advarsler fra erfarne psykiatere.
- 2 May 2017
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 137 (9) , 596
Open AccessRe: Psykiatriens indre konflikter eksponert
Brev til redaktøren - Helse- og omsorgsdepartementet har pålagt alle helseforetak å innføre medikamentfri behandling av psykoser på tross av sterke advarsler fra erfarne psykiatere.
- Open Access
- 1 December 2015
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 135 (22) , 2023
Re: Flere og gale diagnoser med kriteriebasert diagnostikk
- 1 December 2015
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 135 (22) , 2023
Open AccessRe: Flere og gale diagnoser med kriteriebasert diagnostikk
- Open Access
- 28 January 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (2) , 141
T.K. Larsen svarer:
- 28 January 2014
- Published by Norwegian Medical Association in Tidsskrift for Den norske legeforening
- Vol. 134 (2) , 141
Open AccessT.K. Larsen svarer:
- Open Access
- 27 November 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 319
Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area
Substance misuse is a well-recognized co-morbidity to psychosis and has been linked to poor prognostic outcomes in patients. Researchers have yet to investigate the difference in rates and characteristics between first-episode Substance Induced Psychosis (SIP) and primary psychosis. We aimed at comparing patients with SIP to primary psychosis patients with or without substance misuse at baseline. Thirty SIP patients, 45 primary psychosis patients with substance misuse (PS) and 66 primary psychosis patients without substance misuse (PNS) in a well-defined Norwegian catchment area were included from 2007–2011. Assessments included symptom levels (PANSS), diagnostic interviews (SCID), premorbid function scale (PAS) and global functioning (GAF f/s). Treated incidence for SIP was found to be 6.5/100 000 persons per year, 9.7/100 000 persons per year for PS and 24.1/100 000 persons per year for PNS (15-65 yrs). Patients who had substance misuse (PS and SIP) were more likely to be male. Duration of Untreated Psychosis (DUP) was significantly shorter in the SIP group (5.0 wks., p = 0.003) and these had more positive symptoms on the PANSS (p = 0.049). SIP patients also did poorer on early youth academic levels on the PAS. Yearly treated incidence of SIP is 6.5/100 000 persons per year in a Norwegian catchment area. SIP patients have short DUPs, are more likely to be male, have more positive symptoms at baseline and poorer premorbid academic scores in early adolescence. Follow-up will evaluate stability of diagnosis and characteristics.
- 27 November 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 319
Open AccessTreated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area
Substance misuse is a well-recognized co-morbidity to psychosis and has been linked to poor prognostic outcomes in patients. Researchers have yet to investigate the difference in rates and characteristics between first-episode Substance Induced Psychosis (SIP) and primary psychosis. We aimed at comparing patients with SIP to primary psychosis patients with or without substance misuse at baseline. Thirty SIP patients, 45 primary psychosis patients with substance misuse (PS) and 66 primary psychosis patients without substance misuse (PNS) in a well-defined Norwegian catchment area were included from 2007–2011. Assessments included symptom levels (PANSS), diagnostic interviews (SCID), premorbid function scale (PAS) and global functioning (GAF f/s). Treated incidence for SIP was found to be 6.5/100 000 persons per year, 9.7/100 000 persons per year for PS and 24.1/100 000 persons per year for PNS (15-65 yrs). Patients who had substance misuse (PS and SIP) were more likely to be male. Duration of Untreated Psychosis (DUP) was significantly shorter in the SIP group (5.0 wks., p = 0.003) and these had more positive symptoms on the PANSS (p = 0.049). SIP patients also did poorer on early youth academic levels on the PAS. Yearly treated incidence of SIP is 6.5/100 000 persons per year in a Norwegian catchment area. SIP patients have short DUPs, are more likely to be male, have more positive symptoms at baseline and poorer premorbid academic scores in early adolescence. Follow-up will evaluate stability of diagnosis and characteristics.
- Open Access
- 12 February 2013
- Published by Springer Nature in BMC Health Services Research
- Vol. 13 (1) , 57
Factors associated with involuntary admissions among patients with substance use disorders and comorbidity: a cross-sectional study
To investigate factors associated with involuntary admissions to hospital pursuant to a social services act of patients with substance use disorder by comparing the socio-demographic characteristics, substance use, and psychiatric comorbidities with voluntarily admitted patients.
- 12 February 2013
- Published by Springer Nature in BMC Health Services Research
- Vol. 13 (1) , 57
Open AccessFactors associated with involuntary admissions among patients with substance use disorders and comorbidity: a cross-sectional study
To investigate factors associated with involuntary admissions to hospital pursuant to a social services act of patients with substance use disorder by comparing the socio-demographic characteristics, substance use, and psychiatric comorbidities with voluntarily admitted patients.